Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2017
At a glance
- Drugs Dacomitinib (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Apr 2017 Results (n=28), presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 08 Mar 2017 Planned End Date changed from 1 Apr 2016 to 15 Feb 2018.
- 08 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 15 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History